Sign In
Sign Up
Two Blokes
Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical ben
click to rate
Posted by
Two Blokes
Apr 27
- Filed in
Stock
- 4 views
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR1